The pandemic of the new coronavirus COVID-19 has switched medicine around the world on the primary fight against this infection. Patients with chronic liver diseases require increased attention of doctors during an epidemic, since against the background of an exacerbation of their disease, not only the risk of contracting the COVID 19 viral infection increases, but also its more severe course. Patients with confirmed COVID-19 with severe liver damage - high biochemical activity. According to some reports, patients with a severe course of COVID-19 have an increase in ALT levels, a decrease in the number of platelets, a decrease in the level of albumin, and a connection (although not all indicators) with a higher risk of mortality is possible.

COVID 19, liver damage, prog¬nosis

Ilchenko, L. Yu., Nikitin, I. G., & Fedorov, I. G. (2020). COVID-19 and liver damage. Archive of Internal Medicine, 10 (3 (53)), 188-197. https://doi.org/10.20514/2226-6704-2020-10-3-188-197.

Maev, I.V., & Bordin, D.S. (2020). Management of patients with chronic liver diseases in the context of the COVID-19 pandemic. Methodical recommendations. Moscow.

Mannanova, I.V., Ponezheva, Zh.B., Makashova, V.V., Omarova, Kh.G., Reizis, A.R., & Gorelov, A.V. (2020). some aspects of liver damage in sars-cov-2 infection. COVID-19 preprints. microbe. ru.

Pinchuk, T.V., Orlova, N.V., Suranova, T.G., & Bonkalo, T.I. (2020). Mechanisms of liver damage in COVID-19. Medical Alphabet, (19), 39-46.

Reizis A.R., Ponezheva Zh.B., Makashova V.V., Omarova Kh.G., Mannanova I.V., Gorelov A.V. 2020. Liver damage in COVID-19. Covid19-preprints.microbe.RU. https://doi.org/10.21055/preprints-3111760

Reizis, A.R., Ponezheva, Zh.B., Makashova, V.V., Omarova, Kh.G., Mannanova, I.V., & Gorelov, A.V. (2020). Chronic liver disease during the COVID-19 pandemic.

Akdur, A., Karakaya, E., EH, A. S., Alshalabi, O., Kirnap, M., Arslan, H., ... & Haberal, M. (2020). Coronavirus Disease (COVID-19) in Kidney and Liver Transplant Patients: A Single-Center Experience. Experimental and Clinical Transplantation: Official Journal of the Middle East Society for Organ Transplantation, 18(3), 270-274.

Covid, A. P. A. S. L., Force, T., Lau, G., & Sharma, M. (2020). Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatology International, 1. DOI: 10.1007/s12072–020–10054-w.

Artru, F., Alberio, L., Moradpour, D., & Stalder, G. (2020). Acute immune thrombocytopaenic purpura in a patient with COVID-19 and decompensated cirrhosis. BMJ Case Reports CP, 13(7), e236815. doi:10.1136/bcr-2020-236815

Bangash, M. N., Patel, J., & Parekh, D. (2020). COVID-19 and the liver: little cause for concern. The lancet. Gastroenterology & hepatology, 5(6), 529. https://doi.org/10.1016/S2468–1253(20)30084–4

Jose, R. J., & Manuel, A. (2020). COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine, 8(6), e46-e47. https://doi. org/10.1016/S 2213– 2600(20),30216–2.

Tang N, Li D, Wang X, Sun Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost.; 18: 844–7. https://doi.org/10.1111/jth.14768

Chau, T. N., Lee, K. C., Yao, H., Tsang, T. Y., Chow, T. C., Yeung, Y. C., ... & Lai, C. L. (2004). SARS‐associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology, 39(2), 302-310. https://doi.org/10.1002/hep.20111.

Cui, Y., Tian, M., Huang, D., Wang, X., Huang, Y., Fan, L., ... & Zha, Y. (2020). A 55-day-old female infant infected with 2019 novel coronavirus disease: presenting with pneumonia, liver injury, and heart damage. The Journal of infectious diseases, 221(11), 1775-1781. https://doi.org/10.1093/infdis/jiaa113.

Dahlqvist, G., Ciccarelli, O., Van Vlierberghe, H., Berrevoet, F., Vanwolleghem, T., Ysebaert, D., ... & Pirenne, J. (2020). Liver transplantation during the COVID-19 epidemic: recommendations from the Belgian Liver Intestine Transplant Committee (BeLIAC). Acta Gastro-Enterologica Belgica, 83(2), 340-343. https://doi.org/340-343. 10.3748/wjg.v26.i22.29878

El Kassas, M., Alboraie, M., Al Balakosy, A., Abdeen, N., Afify, S., Abdalgaber, M., ... & Wifi, M. N. (2020). Liver transplantation in the era of COVID-19. Arab Journal of Gastroenterology, 21(2), 69-75. https://doi.org/10.1016/j.ajg.2020.04.019

Ghayda, R. A., Lee, J., Lee, J. Y., Kim, D. K., Lee, K. H., Hong, S. H., ... & Shin, J. I. (2020). Correlations of clinical and laboratory characteristics of COVID-19: A systematic review and meta-analysis. International journal of environmental research and public health, 17(14), 5026. https://doi.org/10.3390/ijerph17145026.

Lang, P. A., Recher, M., Honke, N., Scheu, S., Borkens, S., Gailus, N., ... & Lang, K. S. (2010). Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon‐I‐dependent manner in mice. Hepatology, 52(1), 25-32. https://doi.org/10.1002/hep.23640.

Musa, S. (2020). Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now?. Arab Journal of Gastroenterology, 21(1), 3-8.

Polakos, N. K., Cornejo, J. C., Murray, D. A., Wright, K. O., Treanor, J. J., Crispe, I. N., ... & Pierce, R. H. (2006). Kupffer cell-dependent hepatitis occurs during influenza infection. The American journal of pathology, 168(4), 1169-1178.

Sarin, S. K., Choudhury, A., Lau, G. K., Zheng, M. H., Ji, D., Abd-Elsalam, S., ... & Omata, M. (2020). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatology international, 14(5), 690-700. https://doi.org/10.1007/s12072-020-10072-8

Zhang, C., Shi, L., & Wang, F. S. (2020). Liver injury in COVID-19: management and challenges. The lancet Gastroenterology & hepatology, 5(5), 428-430. https://doi.org/10.1016/S2468–1253(20)30057–1.

Zhao, B., Ni, C., Gao, R., Wang, Y., Yang, L., Wei, J., ... & Lin, X. (2020). Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein & cell, 11(10), 771-775. https://doi.org/10.1007/s13238–020–00718–6

Wu, J., Song, S., Cao, H. C., & Li, L. J. (2020). Liver diseases in COVID-19: Etiology, treatment and prognosis. World journal of gastroenterology, 26(19), 2286. https://doi.org/10.3748/wjg. v26.i19.2286.

Wu, J., Song, S., Cao, H. C., & Li, L. J. (2020). Liver diseases in COVID-19: Etiology, treatment and prognosis. World journal of gastroenterology, 26(19), 2286. https://doi.org/10.3748/wjg. v26.i19.2286.

Khamraev A. A., Yuldasheva D.Kh., Mukhamedova Z.R., Zokirov V. Z. (2021). Clinical-laboratory markers of progression of non-alcoholic fatty liver disease. American Journal of Medicine and Medical Sciences, 11(5): – P. 419-425

Yuldasheva D.H., Muxamedova Z.X., Shadjanova N.S. (2021). Patients with chronic liver disease and COVID-19. Society and innovations, Special Issue – 2. P. 498-503

Yuldasheva, D. H., Zokirov, V. Z., & Gulomova Sh, Q. (2020). Non-alcoholic fatty liver disease: Modern view of the problem. A Multidisciplinary Peer Reviewed Journal, 6(12), 286-292.